Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

BMC Psychiatry

Research Article

Concetta Crivera¹  Wayne Macfadden²  Riad D Dirani²  Lian Mao³  Chris M Kozma⁴  Cherilyn DeSouza⁵ 

[1] Janssen Scientific Affairs, LLC, Raritan, New Jersey, USA;Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA;Johnson & Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA;University of South Carolina, Columbia, South Carolina, USA;Veterans Affairs Medical Center, Kansas City, Missouri, USA;

关键词: Schizophrenia;    Resource Utilization;    Emergency Room Visit;    Baseline Visit;    Incidence Density;   

DOI  :  10.1186/1471-244X-11-168

 received in 2010-08-23, accepted in 2011-10-14,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundSchizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care. This analysis examined health care resource utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting therapy (RLAT).MethodsSchizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE) was a 24-month observational study designed to examine real-world treatment outcomes by prospectively following patients with schizophrenia initiated on RLAT. At baseline visit, prior hospitalization and ER visit dates were obtained for the previous 12 months and subsequent hospitalization visit dates were obtained at 3-month visits, if available. The health care resource utilization outcomes measures observed in this analysis were hospitalizations for any reason, psychiatric-related hospitalizations, and emergency room (ER) visits. Incidence density analysis was used to assess pre-event and postevent rates per person-year (PY).ResultsThe primary medical resource utilization analysis included 435 patients who had a baseline visit, ≥1 postbaseline visits after RLAT initiation, and valid hospitalization dates. The number of hospitalizations and ER visits per PY declined significantly (p < .0001) after initiation with RLAT. A 41% decrease (difference of -0.29 hospitalizations per PY [95% CI: -0.39 to -0.18] from baseline) in hospitalizations for any reason, a 56% decrease (a difference of -0.35 hospitalizations per PY [95% CI: -0.44 to -0.26] from baseline) in psychiatric-related hospitalizations, and a 40% decrease (-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10] from baseline) in ER visits were observed after the baseline period. The percentage of psychiatric-related hospitalizations decreased significantly after RLAT initiation, and patients had fewer inpatient hospitalizations and ER visits (all p < .0001).ConclusionThe results suggest that treatment with RLAT may result in decreased hospitalizations for patients with schizophrenia.Trial RegistrationClinicalTrials.gov: NCT00246194

【 授权许可】

CC BY   
© Crivera et al; licensee BioMed Central Ltd. 2011